RCM
BNTC icon

RA Capital Management’s Benitec Biopharma BNTC Stock Holding History

RA Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8M Hold
1,850,000
– – 0.22% 58
2026
Q1 		$19.7M Hold
1,850,000
– – 0.21% 59
2025
Q4 		$24.9M Buy
+1,850,000
New +$25.6M 0.26% 46
2015
Q4 		– Sell
-551
Closed -$864K – 40
2015
Q3 		$864K Buy
+551
New +$1.03M 0.12% 44

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RA Capital Management's BNTC Position: Q2 2026 in Review

RA Capital Management held its Benitec Biopharma (BNTC) position steady in Q2 2026 at 1,850,000 shares worth $24.8M. The position accounts for 0.22% of the portfolio, ranked #58.

RA Capital Management first reported a position in BNTC in Q3 2015 and has held it in 4 quarters since. The position peaked at $24.9M in Q4 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • RA Capital Management held 1,850,000 shares of Benitec Biopharma worth $24.8M as of Q2 2026.
  • RA Capital Management left its Benitec Biopharma share count unchanged in Q2 2026.
  • Benitec Biopharma made up 0.22% of RA Capital Management's portfolio in Q2 2026, its #58 holding.
  • RA Capital Management first reported a position in Benitec Biopharma in Q3 2015 and has held it in 4 quarters since.
  • RA Capital Management's Benitec Biopharma position peaked at $24.9M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.